Peter Verwaijen - Egetis Therapeutics Global Strategy

All Insiders . Sweden . 
Stock . Egetis Therapeutics AB . Stakeholders . Insider . Peter Verwaijen
EGTX Stock  SEK 5.34  0.06  1.11%   

Insider

Peter Verwaijen is Global Strategy of Egetis Therapeutics AB
Phone46 86 79 72 10
Webhttps://www.egetis.com

Egetis Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.136) % which means that it has lost $0.136 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2602) %, meaning that it generated substantial loss on money invested by shareholders. Egetis Therapeutics' management efficiency ratios could be used to measure how well Egetis Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Egetis Therapeutics AB has accumulated 4.88 M in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Egetis Therapeutics has a current ratio of 3.47, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Egetis Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Egetis Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Egetis Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Egetis to invest in growth at high rates of return. When we think about Egetis Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Christopher BirdBioPorto
N/A
Paul MScBavarian Nordic
56
JeanChristophe MayBavarian Nordic
56
Neil CPABioPorto
55
Henrik MScBavarian Nordic
58
Jennifer ZondermanBioPorto
N/A
Anthony PareBioPorto
60
Gry LarsenBioPorto
N/A
Anu KernsBavarian Nordic
51
EjvindgensencBrain AS
N/A
Lars UttenthalBioPorto
N/A
Rolf SrensenBavarian Nordic
N/A
Russell ThirskBavarian Nordic
N/A
Nis KruseBioPorto
N/A
Niels KristensencBrain AS
N/A
Tony SummerlincBrain AS
N/A
Laurence MoerloozeBavarian Nordic
59
Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. Egetis Therapeutics operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people. Egetis Therapeutics AB (EGTX) is traded on Stockholm Exchange in Sweden and employs 17 people.

Management Performance

Return On Equity-0.26
Return On Asset-0.14

Egetis Therapeutics Leadership Team

Elected by the shareholders, the Egetis Therapeutics' board of directors comprises two types of representatives: Egetis Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Egetis. The board's role is to monitor Egetis Therapeutics' management team and ensure that shareholders' interests are well served. Egetis Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Egetis Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Torsten Almn, Founder
Louis Ignarro, Founder
Rob Towart, Founder
Associate Brurok, Founder
Yilmaz Mahshid, Chief Officer
Ingemar Lundstrm, Founder
MBA MBA, Chief Officer
Peter Verwaijen, Global Strategy
Nicklas Westerholm, Chief Officer
Karl Hard, Head VP

Egetis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Egetis Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.26
Return On Asset-0.14
Operating Margin(7.54) %
Current Valuation698.73 M
Shares Outstanding249.59 M
Shares Owned By Insiders52.07 %
Shares Owned By Institutions14.16 %
Price To Book1.52 X
Price To Sales42.39 X
Revenue38.24 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Egetis Stock Analysis

When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY